Teck Resources Ltd (TCK) 17.89 $TCK SmarTrend Watching

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Teck Resources Ltd (TCK) 17.89 $TCK

SmarTrend Watching for Potential Pullback in Shares of Teck Resources After 4.94% Gain
Comtex SmarTrend(R) - 2 hrs 24 mins ago
Teck Resources (NYSE:TCK) traded in a range yesterday that spanned from a low of $17.24 to a high of $17.90. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $17.43 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TCK: 17.89 (+0.90)

After Yesterday's Rally of 4.94% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 2 hrs 26 mins ago
Teck Resources (NYSE:TCK) traded in a range yesterday that spanned from a low of $17.24 to a high of $17.90. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $17.43 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TCK: 17.89 (+0.90)

Uptrend Call Working As Teck Resources Stock Rises 46.5% (TCK)
Comtex SmarTrend(R) - Tue Sep 06, 12:40AM CDT
SmarTrend identified an Uptrend for Teck Resources (NYSE:TCK) on June 7th, 2016 at $11.60. In approximately 3 months, Teck Resources has returned 46.47% as of today's recent price of $16.99.
TCK: 17.89 (+0.90)

Teck Resources Set to Possibly Pullback After Yesterday's Rally of 3.27%
Comtex SmarTrend(R) - Fri Sep 02, 1:30PM CDT
Teck Resources (NYSE:TCK) traded in a range yesterday that spanned from a low of $16.84 to a high of $17.43. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $17.20 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TCK: 17.89 (+0.90)

Look for Shares of Teck Resources to Potentially Pullback after Yesterday's 3.27% Rise
Comtex SmarTrend(R) - Fri Sep 02, 1:28PM CDT
Teck Resources (NYSE:TCK) traded in a range yesterday that spanned from a low of $16.84 to a high of $17.43. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $17.20 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TCK: 17.89 (+0.90)

Teck Announces Acquisition of Securities of Jet Gold
Marketwired - Tue Aug 30, 10:00PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug 30, 2016) - Teck Resources Limited (TSX: TCK.A and TCK.B, NYSE: TCK) ("Teck" announced today that it acquired 8,333,333 common shares, and a $389,117 principal amount convertible debenture of Jet Gold Corp. ("Jet Gold". Jet Gold issued the securities in satisfaction of $889,117 of indebtedness owing to a Teck subsidiary. Jet Gold had assumed the indebtedness in connection with its indirect acquisition of control over a 30% interest in Haib Minerals (PTY) Ltd., in which Teck indirectly holds a 70% interest. The common shares were issued for an aggregate price of $500,000, and the convertible debenture was issued for a price of $389,117. No cash consideration was paid by Teck and the purchase price was fully satisfied by set-off against the assumed indebtedness.
TCK: 17.89 (+0.90)

Irving Resources Enters Into a Technical Advisor Consulting Agreement
Marketwire Canada - Tue Aug 30, 8:02AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug 30, 2016) - Irving Resources Inc. (CSE:IRV) ("Irving" or the "Company" is pleased to announce that it has entered into a technical advisor consulting agreement with Mr. Hidetoshi Takaoka.
TCK: 17.89 (+0.90)

Teck Resources Has Returned 45.1% Since SmarTrend Recommendation (TCK)
Comtex SmarTrend(R) - Mon Aug 29, 1:03PM CDT
SmarTrend identified an Uptrend for Teck Resources (NYSE:TCK) on June 7th, 2016 at $11.60. In approximately 3 months, Teck Resources has returned 45.09% as of today's recent price of $16.83.
TCK: 17.89 (+0.90)

Teck Resources Shares Up 37.2% Since SmarTrend's Buy Recommendation (TCK)
Comtex SmarTrend(R) - Fri Aug 19, 12:57PM CDT
SmarTrend identified an Uptrend for Teck Resources (NYSE:TCK) on June 7th, 2016 at $11.60. In approximately 2 months, Teck Resources has returned 37.24% as of today's recent price of $15.92.
TCK: 17.89 (+0.90)

Frontier Oil Sands Mine Project - Public Comment Invited
CNW Group - Wed Aug 17, 1:57PM CDT
The Joint Review Panel reviewing the proposed Frontier Oil Sands Mine Project is seeking public comments on the Environmental Impact Assessment (EIA), the project applications under the Oil Sands Conservation Act, Environmental Protection and Enhancement Act, and Water Act, and on additional information submitted by the proponent, Teck Resources Ltd.
TCK: 17.89 (+0.90)

Shares of TCK Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 12, 12:38AM CDT
SmarTrend identified an Uptrend for Teck Resources (NYSE:TCK) on June 7th, 2016 at $11.60. In approximately 2 months, Teck Resources has returned 41.55% as of today's recent price of $16.42.
TCK: 17.89 (+0.90)

Teck Resources Rises 4.47% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Aug 08, 1:39PM CDT
Teck Resources (NYSE:TCK) traded in a range yesterday that spanned from a low of $15.95 to a high of $16.94. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $15.94 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TCK: 17.89 (+0.90)

Upgrade Alert for Teck Resources (TCK)
Comtex SmarTrend(R) - Fri Aug 05, 3:17AM CDT
Teck Resources (NYSE:TCK) was upgraded from Underperform to Market Perform at Raymond James today. The stock closed yesterday at $15.65 on volume of 3.9 million shares, below average daily volume of 11.8 million. Based on a current price of $15.64, Teck Resources is currently 49.6% above its average consensus analyst price target of $7.89. The stock should find initial support at its 50-day moving average (MA) of $8.47 and further support at its 200-day MA of $6.07.
TCK: 17.89 (+0.90)

Mining Stocks Under Review -- Vale, Cliffs Natural Resources, Teck Resources, and Rio Tinto
PR Newswire - Thu Aug 04, 6:30AM CDT
This morning's focus is on the Industrial Metals and Minerals space, and how rising demand, slowing supply, and strong Chinese imports are pushing prices up. The industry outlook is positive as the S&P GSCI Industrial Metals index has risen 8.99% Y-T-D. Stock-Callers.com reviews the following equities and sees where they stand in the market today: Vale S.A. (NYSE: VALE), Cliffs Natural Resources Inc. (NYSE: CLF), Teck Resources Ltd (NYSE: TCK), and Rio Tinto PLC (NYSE: RIO). Learn more about these stocks by downloading their free research reports in PDF format at:
TCK: 17.89 (+0.90), VALE: 5.72 (+0.12), CLF: 5.83 (+0.10), RIO: 31.58 (+0.45)

Downgrade Alert for Teck Resources (TCK)
Comtex SmarTrend(R) - Tue Aug 02, 3:06AM CDT
Teck Resources (NYSE:TCK) was downgraded from Buy to Neutral at Goldman Sachs today. The stock closed yesterday at $15.20 on volume of 6.0 million shares, below average daily volume of 11.8 million. In the past 52 weeks, shares of Teck Resources have traded between a low of $2.56 and a high of $16.20 and closed yesterday at $15.20, which is 494% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.9% while the 50-day MA has advanced 5.0%.
TCK: 17.89 (+0.90)

Teck Reports Unaudited Second Quarter Results for 2016
Marketwire Canada - Thu Jul 28, 4:02AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 28, 2016) -
TCK: 17.89 (+0.90)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading